

Jason A Roberts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/583112/publications.pdf>

Version: 2024-02-01

573
papers

31,801
citations

5248

83
h-index

7136

153
g-index

588
all docs

588
docs citations

588
times ranked

17335
citing authors

#	ARTICLE	IF	CITATIONS
1	Microsampling to support pharmacokinetic clinical studies in pediatrics. <i>Pediatric Research</i> , 2022, 91, 1557-1561.	1.1	6
2	A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 446.e1-446.e7.	2.8	8
3	Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 669-679.	1.1	23
4	Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0137721.	1.4	7
5	Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 19-31.	1.0	31
6	Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 86-102.	1.0	10
7	<i>In vitro</i> effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1041-1044.	1.3	2
8	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2155-2162.	1.9	7
9	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. <i>Antibiotics</i> , 2022, 11, 101.	1.5	4
10	Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible <i>Staphylococcus aureus</i> : is it a viable treatment option?. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106537.	1.1	10
11	Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Pulmonary Infection. <i>MBio</i> , 2022, 13, e0351721.	1.8	11
12	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106513.	1.1	1
13	Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. <i>Intensive Care Medicine</i> , 2022, 48, 311-321.	3.9	91
14	Influence of PEGylated porous silicon nanoparticles on permeation and efflux of an orally administered antibiotic. <i>Materials Today Advances</i> , 2022, 13, 100210.	2.5	7
15	Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection <i>in vitro</i> model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1324-1333.	1.3	6
16	Pandora's box: Paxlovid, prescribing, pharmacists and pandemic. <i>Journal of Pharmacy Practice and Research</i> , 2022, 52, 1-4.	0.5	10
17	Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0167921.	1.4	4
18	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204621.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation. <i>Antibiotics</i> , 2022, 11, 434.	1.5	1
20	Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106572.	1.1	7
21	Indonesian healthcare providers' perceptions and attitude on antimicrobial resistance, prescription and stewardship programs. <i>Future Microbiology</i> , 2022, 17, 363-375.	1.0	5
22	Hospital-Based Antimicrobial Stewardship Programs Used in Low- and Middle-Income Countries: A Scoping Review. <i>Microbial Drug Resistance</i> , 2022, 28, 566-584.	0.9	4
23	Editorial: Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?. <i>Australian Prescriber</i> , 2022, 45, 67-68.	0.5	2
24	Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). <i>Clinical Pharmacokinetics</i> , 2022, 61, 847-856.	1.6	8
25	Perioperative cefazolin prophylaxis in paediatric cardiac surgery: a prospective, cohort study. <i>Annals of Thoracic Surgery</i> , 2022, , .	0.7	1
26	Pharmacokinetics of valganciclovir and voriconazole during prolonged intermittent renal replacement therapy in a lung transplant recipient. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	0
27	Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0214021.	1.4	0
28	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 963-979.	2.0	5
29	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 673-686.	1.6	3
30	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against <i>Pseudomonas aeruginosa</i> Bacteremia in the Hollow-Fiber Infection Model. <i>Microbiology Spectrum</i> , 2022, 10, e0052522.	1.2	4
31	Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1211-1224.	2.8	13
32	Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, , 101080.	0.6	3
33	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0218921.	1.4	8
34	Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
35	Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β -lactamase-producing and non-producing <i>Escherichia coli</i> clinical isolates in a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2448-2455.	1.3	3
36	The <i>Staphylococcus aureus</i> Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. <i>Clinical Infectious Diseases</i> , 2022, 75, 2027-2034.	2.9	27

#	ARTICLE	IF	CITATIONS
37	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2227-2237.	1.3	1
38	Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β -lactamase-producing versus non-producing <i>Escherichia coli</i> in a hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2022, , 106623.	1.1	1
39	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
40	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1369-1378.	2.9	85
41	Ceftriaxone dosing in patients admitted from the emergency department with sepsis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 207-214.	0.8	3
42	Comparative lung distribution of radiolabeled tobramycin between nebulized and intravenous administration in a mechanically-ventilated ovine model, an observational study.. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106232.	1.1	1
43	Oral meropenem for superbugs: challenges and opportunities. <i>Drug Discovery Today</i> , 2021, 26, 551-560.	3.2	22
44	Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients – the role of therapeutic drug monitoring. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 707-718.	2.0	11
45	Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Patients with Normal Renal Clearance: Can It Be a Treatment Option?. <i>Microbial Drug Resistance</i> , 2021, 27, 546-552.	0.9	5
46	Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 271-295.	2.0	5
47	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2021, 60, 655-664.	1.6	16
48	Liquid CO ₂ Formulated Mesoporous Silica Nanoparticles for pH-Responsive Oral Delivery of Meropenem. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1836-1853.	2.6	22
49	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 747-755.	1.0	3
50	PLGA encapsulated β -cyclodextrin-meropenem inclusion complex formulation for oral delivery. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120280.	2.6	17
51	Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. <i>Implementation Science Communications</i> , 2021, 2, 34.	0.8	8
52	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	2.3	41
53	Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.	2.3	16
54	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. <i>Annals of Intensive Care</i> , 2021, 11, 49.	2.2	15

#	ARTICLE	IF	CITATIONS
55	Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of <i>Acinetobacter baumannii</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1943-1952.	1.3	6
56	Antimicrobial dosing in prolonged intermittent renal replacement therapy: a systematic review. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 106-120.	0.5	1
57	The impact of pharmacist-led antifungal stewardship interventions in the hospital setting: a systematic review. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 90-105.	0.5	1
58	Standard of practice in intensive care for pharmacy services. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 165-183.	0.5	11
59	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against <i>Pseudomonas aeruginosa</i> . <i>Drugs in R and D</i> , 2021, 21, 203-215.	1.1	2
60	Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
61	Epidemiology of extended-spectrum β -lactamase and metallo- β -lactamase-producing <i>Escherichia coli</i> in South Asia. <i>Future Microbiology</i> , 2021, 16, 521-535.	1.0	7
62	Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives. <i>Microorganisms</i> , 2021, 9, 1154.	1.6	20
63	Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis. <i>Antibiotics</i> , 2021, 10, 602.	1.5	2
64	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 4483-4491.	1.9	2
65	Letter to the Editor regarding: Ceftriaxone exposure in patients undergoing extracorporeal membrane oxygenation. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106326.	1.1	4
66	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1081-1102.	1.6	4
67	Microfluidic assembly of pomegranate-like hierarchical microspheres for efflux regulation in oral drug delivery. <i>Acta Biomaterialia</i> , 2021, 126, 277-290.	4.1	23
68	Personalized β -lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia. <i>Medicine (United States)</i> , 2021, 100, e26253.	0.4	8
69	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0230720.	1.4	4
70	Standard of practice in infectious diseases for pharmacy services. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 247-264.	0.5	2
71	Optimising Treatment Outcomes for Children and Adults Through Rapid Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre Trial (DIRECT). <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 667680.	1.8	10
72	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17102-17107.	7.2	42

#	ARTICLE	IF	CITATIONS
73	Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing. <i>Antibiotics</i> , 2021, 10, 667.	1.5	14
74	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie</i> , 2021, 133, 17239-17244.	1.6	15
75	Applying Antimicrobial Pharmacokinetic Principles for Complex Patients: Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation and Renal Replacement Therapy. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	1.3	1
76	Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0143821.	1.4	9
77	Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1383-1399.	1.3	8
78	Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support. <i>Frontiers in Pharmacology</i> , 2021, 12, 709332.	1.6	4
79	Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106369.	1.1	2
80	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106431.	1.1	5
81	Dose optimisation of antibiotics used for meningitis. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 581-590.	1.3	10
82	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. <i>Antibiotics</i> , 2021, 10, 100.	1.5	2
83	A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 727-739.	1.6	6
84	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. <i>Critical Care Medicine</i> , 2021, 49, e1063-e1143.	0.4	927
85	Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. <i>Critical Care Medicine</i> , 2021, 49, 1974-1982.	0.4	209
86	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106466.	1.1	12
87	Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Medicine</i> , 2021, 47, 1181-1247.	3.9	1,503
88	A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100970.	0.6	21
89	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 921-933.	1.4	4
90	Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?. <i>Pharmaceutical Research</i> , 2021, 38, 1863-1871.	1.7	0

#	ARTICLE	IF	CITATIONS
91	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 37-66.	0.5	24
92	Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 89-117.	0.5	21
93	Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 3-17.	0.5	9
94	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 67-88.	0.5	36
95	Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study. <i>Antibiotics</i> , 2021, 10, 1559.	1.5	3
96	$\hat{\beta}$ -Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 429-433.	1.3	35
97	Nebulized Tranexamic Acid Therapy for Hemoptysis Associated with Submassive Pulmonary Embolism. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 12-14.	0.7	6
98	Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 327-334.	1.6	13
99	$\hat{\beta}$ -lactam antibiotic versus combined $\hat{\beta}$ -lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105839.	1.1	21
100	Antimicrobial dosing in critical care: A pragmatic adult dosing nomogram. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105837.	1.1	20
101	The challenge of quantifying and managing pharmacokinetic variability of beta-lactams in the critically ill. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 27-29.	0.6	3
102	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales : the Importance of Heteroresistance for Growth Outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	13
103	The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 239-247.	0.8	5
104	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 791-797.	1.3	51
105	Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 274-284.	1.4	8
106	Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?. <i>Current Opinion in Anaesthesiology</i> , 2020, 33, 71-82.	0.9	45
107	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). <i>Intensive Care Medicine</i> , 2020, 46, 245-265.	3.9	97
108	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106180.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	15
110	A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	9
111	β -lactam dosing strategies: Think before you push. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106151.	1.1	6
112	The role of antibiotic pharmacokinetic studies performed post-licensing. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106165.	1.1	3
113	What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?. <i>Pharmaceutics</i> , 2020, 12, 638.	2.0	33
114	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 646.	0.7	11
115	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <i>Pseudomonas aeruginosa</i> in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
116	Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. <i>Antibiotics</i> , 2020, 9, 793.	1.5	6
117	Prolonged Versus Intermittent Infusion of β -Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1237-1250.	1.6	18
118	Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant <i>Acinetobacter baumannii</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106115.	1.1	9
119	What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients?. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 626-630.	1.0	6
120	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
121	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106058.	1.1	4
122	Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e84-e86.	0.5	15
123	Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 501-510.	1.3	16
124	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable <i>Pseudomonas aeruginosa</i> in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
125	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. <i>Pharmaceutical Research</i> , 2020, 37, 96.	1.7	10
126	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	19

#	ARTICLE	IF	CITATIONS
127	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 2020, 46, 1127-1153.	3.9	504
128	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. Pharmacotherapy, 2020, 40, 713-717.	1.2	1
129	Low levels of salicylic acid and salicyluric acid are present in synovial fluid of patients taking aspirin at the time of knee arthroplasty surgery. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1635-1637.	0.9	2
130	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
131	Towards precision medicine: Therapeutic drug monitoringâ€“guided dosing of vancomycin and Î²-lactam antibiotics to maximize effectiveness and minimize toxicity. American Journal of Health-System Pharmacy, 2020, 77, 1104-1112.	0.5	51
132	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, 46, 1404-1417.	3.9	54
133	How to design a study to evaluate therapeutic drug monitoring in infectious diseases?. Clinical Microbiology and Infection, 2020, 26, 1008-1016.	2.8	31
134	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. Clinical Pharmacokinetics, 2020, 59, 1027-1036.	1.6	11
135	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. Frontiers in Pharmacology, 2020, 11, 883.	1.6	14
136	Effectiveness of Vancomycin Dosing Guided by Therapeutic Drug Monitoring in Adult Patients Receiving Extracorporeal Membrane Oxygenation. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
137	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2020, 75, 2633-2640.	1.3	12
138	The risks of medical complacency towards poliomyelitis. Medical Journal of Australia, 2020, 213, 61.	0.8	1
139	Prophylactic Cefazolin Dosing in Women With Body Mass Index ≥ 35 kg m ⁻² Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. Anesthesia and Analgesia, 2020, 131, 199-207.	1.1	14
140	Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. Journal of Pharmaceutical Sciences, 2020, 109, 2070-2078.	1.6	14
141	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.3	18
142	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. Journal of Antimicrobial Chemotherapy, 2020, 75, 726-729.	1.3	8
143	Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. International Journal of Antimicrobial Agents, 2020, 55, 105943.	1.1	16
144	On-Site Therapeutic Drug Monitoring. Trends in Biotechnology, 2020, 38, 1262-1277.	4.9	128

#	ARTICLE	IF	CITATIONS
145	Isolation and rapid sharing of the 2019 novel coronavirus (<scp>SARS</scp> â€CoVâ€2) from the first patient diagnosed with <scp>COVID</scp> â€19 in Australia. Medical Journal of Australia, 2020, 212, 459-462.	0.8	297
146	Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. Journal of Antimicrobial Chemotherapy, 2020, 75, 2641-2649.	1.3	18
147	Editorial: Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic. Australian Prescriber, 2020, 43, 76-77.	0.5	6
148	Australian National Enterovirus Reference Laboratory annual report, 2018. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	7
149	Kidney transplant recipientâ€™s perceptions of blood testing through microsampling and venepuncture. Bioanalysis, 2020, 12, 873-881.	0.6	12
150	Epidemiology and Microbiology of Severe Communityâ€Acquired Pneumonia in Central Australia: A Retrospective Study. Internal Medicine Journal, 2020, , .	0.5	3
151	Linguistic and cultural adaptation to the Portuguese language of antimicrobial dose adjustment software. Einstein (Sao Paulo, Brazil), 2020, 18, eAO5023.	0.3	2
152	Software for dose adjustment of antimicrobials. Implications for plasma concentrations and practical limitations. Einstein (Sao Paulo, Brazil), 2020, 18, eCE5858.	0.3	0
153	Australian National Enterovirus Reference Laboratory annual report, 2015. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	4
154	Australian National Enterovirus Reference Laboratory annual report, 2016. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	1
155	Australian National Enterovirus Reference Laboratory annual report, 2017. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	0
156	Political Ecology. Cambridge Encyclopedia of Anthropology, 2020, , .	0.7	10
157	Physician drug prescribing preferences and availability for ventilation of patients with COVID-19. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, , .	0.0	0
158	Physician drug prescribing preferences and availability for ventilation of patients with COVID-19. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, 22, 271-274.	0.0	0
159	A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics, 2019, 58, 263-270.	1.6	0
160	What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clinical Pharmacokinetics, 2019, 58, 1407-1443.	1.6	106
161	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. International Journal of Antimicrobial Agents, 2019, 54, 351-355.	1.1	2
162	Narrative Study on Pharmacokinetics of Antibiotics among Critically Ill Patients: the Implication on the Pharmacokinetics-Pharmacodynamics Target Attainment. Pharmaceutical Sciences and Research, 2019, 6, .	0.5	0

#	ARTICLE	IF	CITATIONS
163	Antimicrobial therapy during ECMO—Customised dosing with therapeutic drug monitoring: The way to go?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2019, 38, 451-453.	0.6	4
164	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	35
165	Pharmacokinetics of Benzylpenicillin (Penicillin G) during Prolonged Intermittent Renal Replacement Therapy. <i>Chemotherapy</i> , 2019, 64, 17-21.	0.8	6
166	Pharmacokinetics/Pharmacodynamics of β -Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 476-487.	0.8	36
167	Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man. <i>Journal of Chemotherapy</i> , 2019, 31, 419-423.	0.7	2
168	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. <i>Chemotherapy</i> , 2019, 64, 115-118.	0.8	4
169	Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize <i>A Priori</i> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
170	Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. <i>Infection</i> , 2019, 47, 1001-1011.	2.3	66
171	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 741-749.	1.1	14
172	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 201-210.	2.0	17
173	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. <i>Critical Care</i> , 2019, 23, 205.	2.5	22
174	Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial. <i>Trials</i> , 2019, 20, 330.	0.7	31
175	Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1219-1226.	0.8	17
176	Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 623-634.	1.3	36
177	Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer. <i>Bone Marrow Transplantation</i> , 2019, 54, 2110-2116.	1.3	9
178	Obesity in the critically ill: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 757-769.	3.9	283
179	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 503-508.	0.8	8
180	Multidrug-resistant <i>Acinetobacter baumannii</i> infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 726-745.	1.1	20

#	ARTICLE	IF	CITATIONS
181	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 288-292.	1.4	12
182	Augmented renal clearance: A real phenomenon with an uncertain cause. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2019, 38, 335-336.	0.6	14
183	Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study. <i>Journal of Critical Care</i> , 2019, 52, 75-79.	1.0	25
184	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 261-264.	1.1	7
185	Defining optimal dosing of ciprofloxacin in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1662-1669.	1.3	18
186	Clinical Pharmacy Considerations in ICU. , 2019, , 849-865.		0
187	Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. <i>Chemotherapy</i> , 2019, 64, 173-176.	0.8	4
188	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	21
189	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7831-7840.	1.9	11
190	Attainment of therapeutic vancomycin level within the first 24h: Authors' response. <i>Critical Care</i> , 2019, 23, 354.	2.5	1
191	Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 732-739.	1.0	17
192	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	21
193	Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 376-382.	1.0	4
194	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). <i>Therapeutic Drug Monitoring</i> , 2019, 41, 703-713.	1.0	7
195	Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. <i>Anesthesiology</i> , 2019, 131, 344-355.	1.3	17
196	Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 103-112.	1.5	18
197	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 432-441.	1.3	43
198	In vitro removal of anti-infective agents by a novel cytokine adsorbent system. <i>International Journal of Artificial Organs</i> , 2019, 42, 57-64.	0.7	51

#	ARTICLE	IF	CITATIONS
199	Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 234-245.	1.1	45
200	Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. <i>Clinical Pharmacokinetics</i> , 2019, 58, 767-780.	1.6	57
201	Personalized antibiotic dosing for the critically ill. <i>Intensive Care Medicine</i> , 2019, 45, 715-718.	3.9	25
202	Solid nanoparticles for oral antimicrobial drug delivery: a review. <i>Drug Discovery Today</i> , 2019, 24, 858-866.	3.2	86
203	Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 137-142.	1.1	14
204	Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. <i>Anesthesia and Analgesia</i> , 2019, 129, 701-708.	1.1	6
205	Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: Lessons learned from an ancillary study of the IVOIRE trial. <i>Journal of Translational Internal Medicine</i> , 2019, 7, 155-169.	1.0	12
206	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β -lactam antibiotic infusion in critically ill patients with sepsis: BLING III. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2019, 21, 63-68.	0.0	10
207	Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant <i>Pseudomonas Aeruginosa</i> lung abscess on an outpatient antimicrobial program. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 941-942.	1.1	9
208	Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency dialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1647-1650.	1.3	16
209	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
210	Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
211	Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1330-1339.	1.3	63
212	Beta-Lactam Therapeutic Drug Monitoring in the Critically Ill Children. <i>Critical Care Medicine</i> , 2018, 46, 335-337.	0.4	1
213	Re: "Is a randomized trial of a short course of aminoglycoside added to β -lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?" TM Pharmacokinetic/pharmacodynamic considerations. <i>Clinical Microbiology and Infection</i> , 2018, 24, 666-667.	2.8	1
214	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018, 44, 189-196.	3.9	101
215	Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 594-600.	1.1	38
216	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 69-76.	0.8	4

#	ARTICLE	IF	CITATIONS
217	Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. <i>Nature Communications</i> , 2018, 9, 22.	5.8	111
218	Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 995-1003.	1.3	34
219	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 709-719.	1.3	30
220	Predictive performance of a gentamicin population pharmacokinetic model in two western populations of critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 218-225.	1.1	11
221	Characterisation of 40â€­mg/ml and 100â€­mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 93-99.	1.1	4
222	Appropriate Antimicrobial Therapy in Critically Ill Patients. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2018, , 319-342.	0.1	0
223	Individualising Therapy to Minimize Bacterial Multidrug Resistance. <i>Drugs</i> , 2018, 78, 621-641.	4.9	48
224	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. <i>Bioanalysis</i> , 2018, 10, 407-423.	0.6	25
225	Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1399-1405.	1.6	13
226	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 151-157.	1.1	25
227	Maximally effective dosing regimens of meropenem in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 191-198.	1.3	40
228	Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. <i>Clinical Pharmacokinetics</i> , 2018, 57, 559-575.	1.6	87
229	A UHPLCâ€­MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 324-333.	1.4	23
230	The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. <i>Advanced Drug Delivery Reviews</i> , 2018, 123, 65-74.	6.6	46
231	Risk factors for multidrugâ€­resistant Gram-negative infection in burn patients. <i>ANZ Journal of Surgery</i> , 2018, 88, 480-485.	0.3	9
232	Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. <i>Clinical Pharmacokinetics</i> , 2018, 57, 439-454.	1.6	22
233	Impact of Quality Bundle Enforcement by a Critical Care Pharmacist on Patient Outcome and Costs*. <i>Critical Care Medicine</i> , 2018, 46, 199-207.	0.4	47
234	Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis*. <i>Critical Care Medicine</i> , 2018, 46, 236-243.	0.4	85

#	ARTICLE	IF	CITATIONS
235	The authors reply. <i>Critical Care Medicine</i> , 2018, 46, e725-e726.	0.4	0
236	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 17.	0.9	7
237	French legal approach to clinical research. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 607-614.	0.6	153
238	Cerebrospinal fluid penetration of very high-dose meropenem: a case report. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2018, 17, 47.	1.7	13
239	Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. <i>Journal of Thoracic Disease</i> , 2018, 10, S629-S641.	0.6	110
240	How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 555-565.	1.3	22
241	Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy. <i>Chemotherapy</i> , 2018, 63, 203-206.	0.8	9
242	Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 515-517.	0.6	14
243	Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. <i>Journal of Critical Care</i> , 2018, 47, 15-20.	1.0	5
244	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	42
245	Determining the editorial policy of <i>Anaesthesia Critical Care and Pain Medicine (ACCPM)</i> . <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 299-301.	0.6	7
246	Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. <i>Journal of Pharmaceutical Analysis</i> , 2018, 8, 407-412.	2.4	6
247	$\hat{\beta}$ -Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	49
248	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 506-509.	1.1	7
249	Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. <i>Critical Care</i> , 2018, 22, 25.	2.5	28
250	Population pharmacokinetics/pharmacodynamics of micafungin against <i>Candida</i> species in obese, critically ill, and morbidly obese critically ill patients. <i>Critical Care</i> , 2018, 22, 94.	2.5	43
251	Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Annals of Pharmacotherapy</i> , 2018, 52, 965-973.	0.9	14
252	Therapeutic drug monitoring of $\hat{\beta}$ -lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3087-3094.	1.3	124

#	ARTICLE	IF	CITATIONS
253	<i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	27
254	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 693-708.	1.5	12
255	Antibiotic Dosing During Extracorporeal Membrane Oxygenation. , 2018, , 151-171.		2
256	Antibiotic Pharmacodynamics. , 2018, , 17-29.		2
257	Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance. <i>Journal of Neurotrauma</i> , 2017, 34, 137-144.	1.7	49
258	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	54
259	Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with hematological malignancy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 674.e7-674.e13.	2.8	29
260	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	34
261	Association between augmented renal clearance and clinical outcomes in patients receiving β -lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 624-630.	1.1	80
262	Dosing antibiotic prophylaxis during cardiopulmonary bypass—a higher level of complexity? A structured review. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 395-402.	1.1	25
263	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. <i>Intensive Care Medicine</i> , 2017, 43, 1021-1032.	3.9	100
264	Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. <i>Clinical Microbiology and Infection</i> , 2017, 23, 629-639.	2.8	121
265	Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1433-1440.	1.3	20
266	Pharmacokinetic/Pharmacodynamics-Optimized Antimicrobial Therapy in Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 271-286.	0.8	10
267	Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. <i>British Journal of Anaesthesia</i> , 2017, 118, 876-882.	1.5	25
268	Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	42
269	Antibiotic dosing for multidrug-resistant pathogen pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 231-239.	1.3	13
270	Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	21

#	ARTICLE	IF	CITATIONS
271	Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. <i>Clinical Microbiology and Infection</i> , 2017, 23, 640-646.	2.8	62
272	Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. <i>Critical Care Medicine</i> , 2017, 45, 331-336.	0.4	55
273	What's new in pharmacokinetics of antimicrobials in AKI and RRT?. <i>Intensive Care Medicine</i> , 2017, 43, 904-906.	3.9	8
274	Impact of β -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 589-594.	1.1	52
275	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1057-1068.	1.6	32
276	The effect of pharmacists on ward rounds measured by the STOPP/START tool in a specialized geriatric unit. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 178-184.	0.7	11
277	An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Bioanalysis</i> , 2017, 9, 911-924.	0.6	17
278	Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	22
279	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. <i>Surgical Infections</i> , 2017, 18, 846-853.	0.7	31
280	A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. <i>Biomedical Chromatography</i> , 2017, 31, e4030.	0.8	1
281	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 227-231.	1.1	20
282	Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults. <i>Anesthesiology</i> , 2017, 126, 890-908.	1.3	87
283	Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	22
284	Does Furosemide Increase Oxidative Stress in Acute Kidney Injury?. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 221-226.	2.5	25
285	Pharmacokinetic and Pharmacodynamic Tools to Increase Efficacy. , 2017, , 85-98.		1
286	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , 2017, 12, 34.	2.1	47
287	Identifying at-risk patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. <i>Critical Care</i> , 2017, 21, 283.	2.5	17
288	The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence. <i>Gastroenterology Insights</i> , 2017, 9, 6849.	0.7	15

#	ARTICLE	IF	CITATIONS
289	Evolutionary changes in the capsid P2 region of Australian strains of the norovirus GII.Pe_GII.4. <i>Journal of Medical Microbiology</i> , 2017, 66, 1014-1022.	0.7	4
290	Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2017, 19, 8-14.	0.0	4
291	The efficacy and safety of adrenergic blockade after burn injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2016, 80, 146-155.	1.1	44
292	Tigecycline use in the outpatient parenteral antibiotic therapy setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1673-1677.	1.3	6
293	Pharmacodynamic Considerations in Critically Ill Patients. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 537-560.	0.1	1
294	Therapeutic drug monitoring of anti-infective agents in critically ill patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 961-979.	1.3	98
295	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016, 20, 125.	2.5	83
296	Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?. <i>Journal of Critical Care</i> , 2016, 34, 95-102.	1.0	19
297	New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4750-4756.	1.4	45
298	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4577-4584.	1.4	38
299	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	2.5	94
300	Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study. <i>Critical Care Medicine</i> , 2016, 44, e923-e929.	0.4	22
301	Is there a role for microsampling in antibiotic pharmacokinetic studies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 601-614.	1.5	20
302	Should β -lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 436-438.	1.1	18
303	Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5914-5921.	1.4	24
304	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6550-6557.	1.4	38
305	Antibiotic dosing in obesity: a BIG challenge. <i>Critical Care</i> , 2016, 20, 240.	2.5	10
306	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. <i>Bioanalysis</i> , 2016, 8, 2235-2242.	0.6	29

#	ARTICLE	IF	CITATIONS
307	Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6806-6812.	1.4	20
308	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 542-546.	1.1	30
309	Fundamentals of aerosol therapy in critical care. <i>Critical Care</i> , 2016, 20, 269.	2.5	78
310	Erratum to "œls inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients? The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group" <i>Journal of Critical Care</i> 34 (2016) 95"102. <i>Journal of Critical Care</i> , 2016, 35, 230.	1.0	2
311	Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clinical Infectious Diseases</i> , 2016, 63, 575-582.	2.9	334
312	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). <i>Peritoneal Dialysis International</i> , 2016, 36, 421-426.	1.1	11
313	Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?. <i>Clinical Therapeutics</i> , 2016, 38, 1961-1975.	1.1	31
314	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clinical Infectious Diseases</i> , 2016, 63, e61-e111.	2.9	2,405
315	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). <i>World Journal of Emergency Surgery</i> , 2016, 11, 33.	2.1	130
316	Integrated pharmacokinetic"pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2902-2908.	1.3	12
317	Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2016, 35, 311-312.	0.6	2
318	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7402-7406.	1.4	14
319	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 748-752.	1.1	22
320	Polyene Antifungals. , 2016, , 109-115.		0
321	Aminoglycoside Dosing in Obesity. , 2016, , 39-44.		0
322	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC"MS/MS: application to a pilot pharmacokinetic study in humans. <i>Biomedical Chromatography</i> , 2016, 30, 872-879.	0.8	22
323	We need to optimize piperacillin-tazobactam dosing in critically ill patients"but how?. <i>Critical Care</i> , 2016, 20, 163.	2.5	6
324	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.	1.3	38

#	ARTICLE	IF	CITATIONS
325	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4901-4909.	1.4	29
326	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Medicine</i> , 2016, 42, 1535-1545.	3.9	244
327	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2016, 36, 415-420.	1.1	7
328	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 696-702.	1.3	37
329	Does Critical Illness Change Levofloxacin Pharmacokinetics?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1459-1463.	1.4	17
330	<i>In Vivo</i> Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 827-832.	1.4	18
331	Continuous versus Intermittent β -Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 681-691.	2.5	308
332	Isolation and Characterization of Poliovirus in Cell Culture Systems. <i>Methods in Molecular Biology</i> , 2016, 1387, 29-53.	0.4	4
333	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 259-268.	1.1	94
334	LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 34-40.	5.8	40
335	Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety. <i>Respiratory Care</i> , 2016, 61, 1008-1014.	0.8	39
336	The use and risks of antibiotics in critically ill patients. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 667-678.	1.0	25
337	Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1460.	3.8	289
338	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. <i>BMC Infectious Diseases</i> , 2016, 16, 103.	1.3	14
339	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1643-1650.	1.3	16
340	Antibiotic Dosing In Critically Ill Patients Receiving Renal Replacement Therapy. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 497-499.	1.3	4
341	Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. <i>Clinical Microbiology and Infection</i> , 2016, 22, 359-364.	2.8	46
342	A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. <i>Clinical Infectious Diseases</i> , 2016, 62, 1009-1017.	2.9	168

#	ARTICLE	IF	CITATIONS
343	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 521-530.	1.3	21
344	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 464-470.	1.3	36
345	Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 467-72.	1.4	19
346	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	1.3	129
347	Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 208-212.	1.3	64
348	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 206-214.	1.4	11
349	Understanding PK/PD. <i>Intensive Care Medicine</i> , 2016, 42, 1797-1800.	3.9	64
350	Prolonged administration of β -lactam antibiotics – a comprehensive review and critical appraisal. <i>Swiss Medical Weekly</i> , 2016, 146, w14368.	0.8	41
351	Is high-dose β -lactam therapy associated with excessive drug toxicity in critically ill patients?. <i>Minerva Anestesiologica</i> , 2016, 82, 957-65.	0.6	25
352	Antimicrobial Stewardship in Australian Hospitals and Other Settings. <i>Infectious Diseases and Therapy</i> , 2015, 4, 27-38.	1.8	32
353	Anti-Infective Drugs during Continuous Hemodialysis – Using the Bench to Learn What to do at the Bedside. <i>International Journal of Artificial Organs</i> , 2015, 38, 17-22.	0.7	27
354	Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. <i>International Journal of Artificial Organs</i> , 2015, 38, 419-424.	0.7	13
355	Optimizing dosing of antibiotics in critically ill patients. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 497-504.	1.3	41
356	Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. <i>Current Opinion in Critical Care</i> , 2015, 21, 412-420.	1.6	75
357	Does Appropriate Antibiotic Therapy Mean Only Adequate Spectrum and Timing?*. <i>Critical Care Medicine</i> , 2015, 43, 1773-1774.	0.4	6
358	Risk Factors in Hospitalized Patients With Burn Injuries for Developing Heterotopic Ossification – A Retrospective Analysis. <i>Journal of Burn Care and Research</i> , 2015, 36, 465-470.	0.2	41
359	The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0144740.	1.1	24
360	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. <i>Critical Care</i> , 2015, 19, 28.	2.5	111

#	ARTICLE	IF	CITATIONS
361	Optimization of dosing regimens and dosing in special populations. <i>Clinical Microbiology and Infection</i> , 2015, 21, 886-893.	2.8	65
362	Subtleties in practical application of prolonged infusion of β -lactam antibiotics. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 461-463.	1.1	36
363	A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. <i>Critical Care</i> , 2015, 19, 84.	2.5	108
364	Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. <i>Critical Care</i> , 2015, 19, 164.	2.5	181
365	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. <i>Bioanalysis</i> , 2015, 7, 2585-2595.	0.6	45
366	Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. <i>Critical Care</i> , 2015, 19, 437.	2.5	67
367	Antibiotic dose optimization in critically ill patients. <i>Medicina Intensiva (English Edition)</i> , 2015, 39, 563-572.	0.1	2
368	β -Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 278-282.	1.1	93
369	Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 192-195.	1.1	8
370	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 41-45.	1.1	50
371	Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1411-1417.	1.4	26
372	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 528-533.	1.3	21
373	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 92-103.	0.8	68
374	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1495-1502.	1.3	60
375	Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. <i>Clinical Pharmacokinetics</i> , 2015, 54, 783-795.	1.6	107
376	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.	2.5	108
377	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 39-44.	1.1	28
378	Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 121-124.	1.1	6

#	ARTICLE	IF	CITATIONS
379	A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4689-4694.	1.4	19
380	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 509-514.	1.4	23
381	A Multicenter Randomized Trial of Continuous versus Intermittent β -Lactam Infusion in Severe Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1298-1305.	2.5	206
382	The need for cost-effectiveness analyses of antimicrobial stewardship programmes: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 140-149.	1.1	51
383	Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 413-419.	1.1	23
384	Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 742-746.	0.8	3
385	Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5463-5469.	1.4	23
386	Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 249-253.	1.1	56
387	Therapeutic drug monitoring of the β -lactam antibiotics: what is the evidence and which patients should we be using it for?: Figure 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv201.	1.3	118
388	Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. <i>Current Opinion in Pharmacology</i> , 2015, 24, 1-6.	1.7	101
389	The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2671-2677.	1.3	106
390	Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections. <i>Journal of Infection</i> , 2015, 71, 604-607.	1.7	16
391	The authors reply. <i>Critical Care Medicine</i> , 2015, 43, e154-e155.	0.4	1
392	Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 21-27.	1.1	52
393	Streamlined research funding using short proposals and accelerated peer review: an observational study. <i>BMC Health Services Research</i> , 2015, 15, 55.	0.9	20
394	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <i>Escherichia coli</i> and <i>Klebsiella</i> spp (the MERINO trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 24.	0.7	57
395	Even high-dose extended infusions may not yield desired concentrations of β -lactams: the value of therapeutic drug monitoring. <i>Infectious Diseases</i> , 2015, 47, 739-742.	1.4	8
396	Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2369-2375.	1.3	68

#	ARTICLE	IF	CITATIONS
397	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 136-153.	0.8	134
398	Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 647-651.	1.1	20
399	An UHPLC-MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. <i>Bioanalysis</i> , 2015, 7, 2311-2319.	0.6	9
400	Antibiotic dose optimization in critically ill patients. <i>Medicina Intensiva</i> , 2015, 39, 563-572.	0.4	39
401	Assays for therapeutic drug monitoring of β -lactam antibiotics: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 367-375.	1.1	95
402	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	1.4	59
403	Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2854-2861.	1.3	64
404	Enterovirus D68 disease and molecular epidemiology in Australia. <i>Journal of Clinical Virology</i> , 2015, 69, 117-121.	1.6	50
405	A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 39-45.	1.4	28
406	Interethnic Differences in Pharmacokinetics of Antibacterials. <i>Clinical Pharmacokinetics</i> , 2015, 54, 243-260.	1.6	36
407	How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. <i>BMC Infectious Diseases</i> , 2014, 14, 288.	1.3	83
408	Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. <i>Critical Care</i> , 2014, 18, 654.	2.5	47
409	Low Flucloxacillin Concentrations in a Patient With Central Nervous System Infection. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1380-1384.	0.9	20
410	Antimicrobial stewardship of β -lactams in intensive care units. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 581-595.	2.0	12
411	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1364-1388.	0.5	88
412	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. <i>Critical Care</i> , 2014, 18, 565.	2.5	87
413	Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. <i>Critical Care</i> , 2014, 18, 632.	2.5	83
414	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. <i>Critical Care</i> , 2014, 18, 657.	2.5	64

#	ARTICLE	IF	CITATIONS
415	The Impact of Variation in Renal Replacement Therapy Settings on Piperacillin, Meropenem, and Vancomycin Drug Clearance in the Critically Ill. <i>Critical Care Medicine</i> , 2014, 42, 1640-1650.	0.4	103
416	Vancomycin-Associated Nephrotoxicity in the Critically Ill. <i>Critical Care Medicine</i> , 2014, 42, 2527-2536.	0.4	94
417	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2508-2516.	1.3	29
418	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 441-447.	0.8	56
419	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 498-509.	4.6	745
420	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 423-430.	1.1	48
421	The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 77-84.	0.8	50
422	A national survey of renal replacement therapy prescribing practice for acute kidney injury in <scp>M</scp>alaysian intensive care units. <i>Nephrology</i> , 2014, 19, 507-512.	0.7	11
423	Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3533-3537.	1.4	37
424	Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1624-1632.	1.3	35
425	Simultaneous determination of seven β -lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 960, 134-144.	1.2	82
426	An international, multicentre survey of β -lactam antibiotic therapeutic drug monitoring practice in intensive care units. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1416-1423.	1.3	185
427	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	2.9	843
428	Meeting the challenges of advanced drug delivery in critical illness. <i>Advanced Drug Delivery Reviews</i> , 2014, 77, 1-2.	6.6	0
429	Therapeutic drug monitoring of antibiotics – Author's reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1181.	4.6	1
430	Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 409-415.	1.1	47
431	Difference in maxillary sinus volumes of patients with cleft lip and palate. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2014, 78, 2234-2236.	0.4	25
432	Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?. <i>Critical Care</i> , 2014, 18, 156.	2.5	16

#	ARTICLE	IF	CITATIONS
433	Reply to Rhodes et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 907-908.	2.9	2
434	Risk factors for target non-attainment during empirical treatment with β -lactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 1340-1351.	3.9	147
435	Amikacin dosing in the ICU: we now know more, but still not enough. <i>Intensive Care Medicine</i> , 2014, 40, 1033-1035.	3.9	3
436	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.	2.5	87
437	Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4094-4102.	1.4	72
438	Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 343-348.	1.1	45
439	Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 163-167.	1.1	27
440	Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange?. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 570-571.	1.1	8
441	Cefazolin plasma protein binding in different human populations: More than cefazolin-albumin interaction. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 199-200.	1.1	16
442	Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2797-2803.	1.3	30
443	Antimicrobial stewardship activities: a survey of Queensland hospitals. <i>Australian Health Review</i> , 2014, 38, 557.	0.5	30
444	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 289-293.	1.1	63
445	Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2600-2608.	1.3	48
446	Protein Binding of β -Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6165-6170.	1.4	185
447	Reply to Soman et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 323-324.	2.9	0
448	Clinical implications of antibiotic pharmacokinetic principles in the critically ill. <i>Intensive Care Medicine</i> , 2013, 39, 2070-2082.	3.9	192
449	Can optimal drug dosing during ECMO improve outcomes?. <i>Intensive Care Medicine</i> , 2013, 39, 2237-2237.	3.9	7
450	Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 384-389.	1.1	53

#	ARTICLE	IF	CITATIONS
451	Echovirus 19 associated with a case of acute flaccid paralysis. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, E239-42.	0.4	4
452	The Clinical Relevance of Plasma Protein Binding Changes. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1-8.	1.6	225
453	Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2013, 56, 236-244.	2.9	317
454	β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 162-166.	1.1	65
455	The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. <i>BMC Anesthesiology</i> , 2013, 13, 7.	0.7	38
456	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 90-93.	1.1	24
457	Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 564-568.	1.1	44
458	Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. <i>Critical Care</i> , 2013, 17, R35.	2.5	149
459	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. <i>Critical Care</i> , 2013, 17, R84.	2.5	166
460	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. <i>BMJ Open</i> , 2013, 3, e003511.	0.8	2
461	Electron microscope detection of an endogenous infection of retrovirus-like particles in L20B cells. <i>Microscopy (Oxford, England)</i> , 2013, 62, 485-486.	0.7	5
462	How should we dose antibiotics for pneumonia in the ICU?. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 189-195.	1.3	10
463	Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. <i>Journal of Neurosurgery</i> , 2013, 118, 297-301.	0.9	38
464	Defining Antibiotic Dosing in Lung Infections. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 121-128.	0.3	18
465	A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2859-2865.	1.3	52
466	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 726-727.	1.3	42
467	Optimal Doripenem Dosing Simulations in Critically Ill Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility*. <i>Critical Care Medicine</i> , 2013, 41, 489-495.	0.4	81
468	A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2013, 15, 179-85.	0.0	3

#	ARTICLE	IF	CITATIONS
469	Improving antibiotic dosing in special situations in the ICU. <i>Current Opinion in Critical Care</i> , 2012, 18, 460-471.	1.6	86
470	Infusional \hat{I}^2 -lactam antibiotics in febrile neutropenia. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 619-625.	1.3	20
471	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq1 1 0.784314 rgBT /Over 2.2 18	2.2	18
472	Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5568-5574.	1.4	24
473	Evaluation of Medication-Related Problems in Medication Reviews: A Comparative Perspective. <i>Annals of Pharmacotherapy</i> , 2012, 46, 972-982.	0.9	19
474	Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patientsâ€™ A One-Year Prospective Study. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 160-164.	1.0	65
475	Australian Clinical Pharmacy Award 2012. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 308-310.	0.5	0
476	Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. <i>Critical Care Medicine</i> , 2012, 40, 1523-1528.	0.4	185
477	Subtherapeutic Initial \hat{I}^2 -Lactam Concentrations in Select Critically Ill Patients. <i>Chest</i> , 2012, 142, 30-39.	0.4	354
478	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. <i>Critical Care</i> , 2012, 16, R194.	2.5	233
479	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. <i>Burns</i> , 2012, 38, 685-690.	1.1	53
480	Investigation of a predicted N-terminal amphipathic \hat{I}^{\pm} -helix using atomistic molecular dynamics simulation of a complete prototype poliovirus virion. <i>Journal of Molecular Graphics and Modelling</i> , 2012, 38, 165-173.	1.3	18
481	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. <i>BMC Anesthesiology</i> , 2012, 12, 29.	0.7	90
482	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. <i>BMC Infectious Diseases</i> , 2012, 12, 152.	1.3	47
483	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 1-10.	1.1	45
484	Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 69-72.	1.1	47
485	How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 187-192.	1.1	62
486	What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 455-457.	1.1	84

#	ARTICLE	IF	CITATIONS
487	Quantification of seven β -lactam antibiotics and two β -lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 416-422.	1.1	85
488	A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 907, 178-184.	1.2	107
489	Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. <i>Journal of Critical Care</i> , 2012, 27, 741.e9-741.e18.	1.0	257
490	Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review. <i>Surgical Infections</i> , 2012, 13, 9-17.	0.7	27
491	Editorial Commentary: Closing the Loop--A Colistin Clinical Study to Confirm Dosing Recommendations From PK/PD Modeling. <i>Clinical Infectious Diseases</i> , 2012, 54, 1727-1729.	2.9	20
492	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. <i>Annals of Intensive Care</i> , 2012, 2, 37.	2.2	85
493	Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. <i>Annals of Intensive Care</i> , 2012, 2, 35.	2.2	149
494	How do I Adjust Antimicrobial Daily Dosage in Patients with MODS? A Pharmacist's Contribution. , 2012, , 199-217.		0
495	Therapeutic drug monitoring of antimicrobials. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 27-36.	1.1	263
496	β -lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 489-496.	0.9	74
497	The association of picornaviruses with gastroenteritis. <i>Microbiology Australia</i> , 2012, 33, 82.	0.1	0
498	Antibiotic Therapy of Pneumonia in Critical Care. <i>Current Respiratory Medicine Reviews</i> , 2012, 8, 228-238.	0.1	0
499	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 105-11.	0.0	19
500	Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 312-5.	0.0	14
501	A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. <i>Critical Care</i> , 2011, 15, R139.	2.5	174
502	Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 227-231.	1.3	119
503	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 90-92.	1.1	7
504	Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program in Asia-Pacific Region. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 225-229.	1.1	23

#	ARTICLE	IF	CITATIONS
505	Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock. <i>Critical Care Clinics</i> , 2011, 27, 19-34.	1.0	118
506	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 99-110.	1.6	325
507	Pharmacokinetic evaluation of fluconazole in critically ill patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1431-1440.	1.5	13
508	Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing?*. <i>Critical Care Medicine</i> , 2011, 39, 602-603.	0.4	20
509	Editorial [Hot Topic: Relevance of Pharmacokinetics to Antibiotic Dosing in Critically Ill Patients (Guest Editor: Jason A. Roberts)]. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 1981-1982.	0.9	3
510	Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2070-2079.	0.9	53
511	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. <i>Internal Medicine Journal</i> , 2011, 41, 537-543.	0.5	69
512	Implications of augmented renal clearance in critically ill patients. <i>Nature Reviews Nephrology</i> , 2011, 7, 539-543.	4.1	169
513	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. <i>BMC Anesthesiology</i> , 2011, 11, 3.	0.7	43
514	The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. <i>BMC Anesthesiology</i> , 2011, 11, 5.	0.7	7
515	Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5238-5242.	1.4	68
516	Antibiotic Dosing in Multiple Organ Dysfunction Syndrome. <i>Chest</i> , 2011, 139, 1210-1220.	0.4	80
517	Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial. <i>BMJ Open</i> , 2011, 1, e000334-e000334.	0.8	11
518	Population Pharmacokinetics of Fluconazole in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration: Using Monte Carlo Simulations To Predict Doses for Specified Pharmacodynamic Targets. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5868-5873.	1.4	48
519	Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2704-2709.	1.4	197
520	Optimizing Antibiotic Use in the Intensive Care Unit. <i>Clinical Pulmonary Medicine</i> , 2010, 17, 162-169.	0.3	1
521	Pharmacokinetics and pharmacodynamics in critically ill patients. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 472-478.	0.9	49
522	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2039-2043.	1.2	172

#	ARTICLE	IF	CITATIONS
523	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1771-1778.	1.3	102
524	Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2974-2978.	1.4	67
525	Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3635-3640.	1.4	65
526	Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill. <i>Current Respiratory Medicine Reviews</i> , 2010, 6, 253-263.	0.1	0
527	First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 156-163.	1.1	154
528	Therapeutic drug monitoring of β -lactams for critically ill patients: unwarranted or essential?. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 419-420.	1.1	68
529	Augmented renal clearance in the Intensive Care Unit: an illustrative case series. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 606-608.	1.1	81
530	Therapeutic drug monitoring of β -lactams in critically ill patients: proof of concept. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 332-339.	1.1	305
531	Antimicrobial chemotherapy and lung microdialysis: a review. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 491-500.	1.1	38
532	Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2010, 49, 1-16.	1.6	313
533	Pharmacokinetic evaluation of piperacillin-tazobactam. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1017-1031.	1.5	65
534	New approaches to enterovirus identification. <i>Microbiology Australia</i> , 2010, 31, 138.	0.1	1
535	Enterovirus. , 2010, , 229-233.		0
536	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. <i>Clinical Biochemist Reviews</i> , 2010, 31, 21-4.	3.3	98
537	A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2010, 12, 162-70.	0.0	8
538	Imported Case of Poliomyelitis, Melbourne, Australia, 2007. <i>Emerging Infectious Diseases</i> , 2009, 15, 63-65.	2.0	36
539	Public Health Response to Imported Case of Poliomyelitis, Australia, 2007. <i>Emerging Infectious Diseases</i> , 2009, 15, 1733-1737.	2.0	6
540	Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. <i>BMC Nephrology</i> , 2009, 10, 42.	0.8	9

#	ARTICLE	IF	CITATIONS
541	Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 142-150.	1.3	294
542	Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model. <i>Journal of Clinical Virology</i> , 2009, 44, 268-271.	1.6	6
543	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 383-384.	1.1	5
544	Pharmacokinetic issues for antibiotics in the critically ill patient. <i>Critical Care Medicine</i> , 2009, 37, 840-851.	0.4	755
545	Dose matters: Dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. <i>Critical Care Medicine</i> , 2009, 37, 2491-2492.	0.4	0
546	Midazolam Metabolism: Implications for Individualised Dosing?. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 198-201.	0.5	3
547	A systematic review on clinical benefits of continuous administration of β -lactam antibiotics*. <i>Critical Care Medicine</i> , 2009, 37, 2071-2078.	0.4	244
548	Tissue Distribution of Beta-Lactam Antibiotics: Continuous versus Bolus Dosing. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 219-222.	0.5	6
549	Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?. <i>Critical Care Medicine</i> , 2009, 37, 926-933.	0.4	166
550	Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. <i>Anaesthesia</i> , 2008, 63, 714-718.	1.8	14
551	A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 240-244.	1.1	13
552	Antibiotic resistance—What's dosing got to do with it?. <i>Critical Care Medicine</i> , 2008, 36, 2433-2440.	0.4	299
553	Continuous infusion of β -lactams in the intensive care unit—Best way to hit the target?*. <i>Critical Care Medicine</i> , 2008, 36, 1663-1664.	0.4	15
554	Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. <i>Current Opinion in Critical Care</i> , 2008, 14, 390-396.	1.6	90
555	Continuous Infusion of Time-dependent Antibiotics. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 167-172.	0.3	1
556	Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock. , 2008, , 97-136.		2
557	Optimizing Use of β -Lactam Antibiotics in the Critically Ill. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 579-585.	0.8	17
558	Pharmacists Investigating Adverse Penicillin Responses—Pilot Study. <i>Journal of Pharmacy Practice and Research</i> , 2007, 37, 200-203.	0.5	0

#	ARTICLE	IF	CITATIONS
559	Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted. <i>Critical Care</i> , 2007, 11, 413.	2.5	0
560	Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 117-128.	1.1	29
561	Continuous infusion of β -lactam antibiotics in severe infections: a review of its role. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 11-18.	1.1	161
562	Annual report of the Australian National Poliovirus Reference Laboratory, 2006. <i>Communicable Diseases Intelligence Quarterly Report</i> , 2007, 31, 263-9.	0.6	2
563	Antibacterial Dosing in Intensive Care. <i>Clinical Pharmacokinetics</i> , 2006, 45, 755-773.	1.6	247
564	Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 285-291.	1.3	111
565	Development of Multiplex PCRs for Detection of Common Viral Pathogens and Agents of Congenital Infections. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5102-5110.	1.8	78
566	BK viral infection in an Australian pediatric renal transplant population. <i>Pediatric Transplantation</i> , 2004, 8, 480-484.	0.5	38
567	Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. <i>Lancet, The</i> , 2001, 358, 121-122.	6.3	170
568	Host-Bacteria Interactions in the Pathogenesis of Urinary Tract Infections. <i>Pediatrics International</i> , 1986, 28, 129-147.	0.2	0
569	Australian National Enterovirus Reference Laboratory annual report, 2019. <i>Communicable Diseases Intelligence</i> (2018), 0, 44, .	0.3	3
570	Pharmacokinetics of Amoxicillin and Cefepime During Prolonged Intermittent Renal Replacement Therapy: A Case Report. , 0, , 78-83.		1
571	Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR <i>Pseudomonas aeruginosa</i> Infections: An Observational Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 0, , .	0.6	2
572	Vancomycin population pharmacokinetic modeling in children using Bayesian estimation and a Non Parametric Approach. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0
573	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	4